Preeclampsia inactivates glucose-6-phosphate dehydrogenase and impairs the redox status of erythrocytes and fetal endothelial cells.
Inactivation of glucose-6-phosphate dehydrogenase (G6PD) may contribute to vascular dysfunction in preeclampsia, and oxidative stress has been implicated in the pathogenesis of this disease. We have compared the susceptibility of erythrocytes and human umbilical vein endothelial cells (HUVEC) to oxidative stress in women with normotensive or preeclamptic pregnancies. The redox status of erythrocytes was also correlated with neutrophil-mediated superoxide (O(2)(.-)) production in women recruited to the "Vitamins in Preeclampsia" (VIP) trial. Erythrocytes and HUVEC from women with preeclampsia demonstrated impaired redox regulation and diminished response to glucose, detectable at 14-20 weeks gestation prior to onset of the clinical disease. Hexokinase and G6PD activities were decreased in erythrocytes and G6PD activity was decreased in HUVEC from preeclamptic pregnancies. Phorbol-ester-stimulated O(2)(.-) was enhanced in preeclamptic neutrophils. Impaired redox regulation in erythrocytes and HUVEC in preeclampsia may be due to diminished hexokinase and G6PD activities resulting from increased release of reactive oxygen species from activated neutrophils. Our findings provide the first evidence that decreased G6PD activity in preeclampsia is associated with impaired redox regulation in erythrocytes and fetal endothelial cells. The deficiency in G6PD in preeclampsia potentially accounts for the lack of protection against oxidative stress afforded by antioxidant vitamin C/E supplementation in the VIP trial.
Afzal-Ahmed
Iram
I
Cardiovascular Division, School of Medicine, King's College London, 150 Stamford Street, London SE1 9NH, UK.
Mann
Giovanni E
GE
Shennan
Andrew H
AH
Poston
Lucilla
L
Naftalin
Richard J
RJ
D000328:Adult; D000975:Antioxidants; D015153:Blotting, Western; D004730:Endothelium, Vascular / Q000201:enzymology* / Q000473:pathology; D004912:Erythrocytes / Q000201:enzymology* / Q000473:pathology; D005260:Female; D005333:Fetus / Q000378:metabolism* / Q000473:pathology; D005947:Glucose / Q000494:pharmacology; D005954:Glucosephosphate Dehydrogenase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006593:Hexokinase / Q000378:metabolism; D006801:Humans; D008623:Mercaptoethanol / Q000378:metabolism; D018375:Neutrophil Activation; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D011225:Pre-Eclampsia / Q000378:metabolism* / Q000473:pathology; D011247:Pregnancy; D013481:Superoxides / Q000378:metabolism; D014471:Umbilical Veins / Q000201:enzymology* / Q000473:pathology
D000975:Antioxidants; D013481:Superoxides; D008623:Mercaptoethanol; D005954:Glucosephosphate Dehydrogenase; D006593:Hexokinase; D005947:Glucose